Related Experiment Video
Updated: Jan 31, 2026

Isolation of CD146+ Resident Lung Mesenchymal Stromal Cells from Rat Lungs
Published on: June 17, 2016
Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer
Soon-Ki Hong1, Haeseung Lee2, Ok-Seon Kwon1
1College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
Abstract:
Even when targets responsible for chemoresistance are identified, drug development is often hampered due to the poor druggability of these proteins. We systematically analyzed therapy-resistance with a large-scale cancer cell transcriptome and drug-response datasets and predicted the candidate drugs based on the gene expression profile. Our results implicated the epithelial-mesenchymal transition as a common mechanism underlying resistance to chemotherapeutic drugs. Notably, we identified ITGB3, whose expression was abundant in both drug resistance and mesenchymal status, as a promising target to overcome chemoresistance. We also confirmed that depletion of ITGB3 sensitized cancer cells to conventional chemotherapeutic drugs by modulating the NF-κB signaling pathway. Considering the poor druggability of ITGB3 and the lack of feasible drugs to directly inhibit this protein, we took an in silico screening for drugs mimicking the transcriptome-level changes caused by knockdown of ITGB3. This approach successfully identified atorvastatin as a novel candidate for drug repurposing, paving an alternative path to drug screening that is applicable to undruggable targets.
Insights
Researchers identified epithelial-mesenchymal transition as a cause of chemoresistance and found that targeting ITGB3 can overcome this resistance. Atorvastatin was identified as a potential drug to repurpose for treating chemoresistant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemoresistance in cancer is a major clinical challenge, often linked to targets with poor druggability.
- Systematic analysis of cancer cell transcriptomes and drug-response data is crucial for identifying resistance mechanisms and predicting therapeutic strategies.
Discussion:
- Epithelial-mesenchymal transition (EMT) is a common mechanism underlying resistance to chemotherapeutic drugs.
- Integrin beta 3 (ITGB3) expression correlates with both drug resistance and mesenchymal phenotype, making it a potential target to overcome chemoresistance.
- ITGB3 depletion sensitizes cancer cells to chemotherapy by modulating the NF-κB signaling pathway.
Key Insights:
- ITGB3 is identified as a promising target to overcome chemoresistance.
- Depletion of ITGB3 enhances sensitivity to conventional chemotherapeutic drugs.
- In silico screening identified atorvastatin as a drug repurposing candidate for chemoresistant cancers by mimicking ITGB3 knockdown effects.
Outlook:
- The study presents an alternative drug screening approach for undruggable targets by mimicking transcriptome-level changes.
- Atorvastatin shows potential for repurposing to combat chemoresistance.
- Further research can explore the therapeutic efficacy of atorvastatin in combination with conventional chemotherapies.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
Drug Dependence
Lung Capacity
pH Scale
Frequency-dependent Selection
Scaling

